This Phase I first-in-human is designed to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of M201-A administered by single continuous intravenous injection in Healthy Japanese subjects.

Not Provided

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

• Japanese Healthy Male subjects
• Age 20 to less than 40 years of age
• Body Mass Index (BMI) of 18.5 to less than 25.0 kg/m2
• Written informed consent must be obtained on a voluntary basis before any assessment is performed.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

• Presence or past medical history of hepatic impairments, renal impairments, cardiovascular disease, gastrointestinal disease and others which are inappropriate for participating in this clinical trial
• Past medical history of cancer, cerebral infarction or cardiac infarction
• Presence or past medical history of allergic reactions or idiosyncrasies to food, medicinal substance and metallic materials
• QTcF > 450ms at the screening examination
• NT-proBNP > 125 pg/mL at the screening examination
• Any risk factors of Torsades de Pointes including such as heart failure, hypokalemia, long QT interval syndrome due to family medical history